Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that AstraZeneca's Recentin plus FOLFOX4 will earn 10 percent patient share first-line stage IV colorectal cancer market in the U.S. by 2016. Additionally, oncologists indicate that they would prescribe this combination to 33 percent of their patients in the first-line setting for stage IV colorectal cancer.

"Although oncologists interviewed are eager to prescribe Recentin plus FOLFOX4, competition from the established Avastin will limit patient share," said Marcus Hoyle, analyst at Decision Resources. "According to oncologists interviewed, physicians are gaining familiarity and comfort with prescribing Avastin in the first-line setting, limiting the uptake of emerging agents."

According to the new report entitled Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival over IFL plus Bevacizumab to Reach Blockbuster Status, physicians indicate that the most promising emerging therapies for the treatment of colorectal cancer will not match the current gold standard, CAPOX plus bevacizumab. CAPOX plus bevacizumab consists of Roche's Xeloda, Sanofi-Aventis's Eloxatin/Eloxatine, Yakult-Honsha's Elplat plus Roche/Genentech/Chugai's Avastin. All three emerging therapies- AstraZeneca's Recentin (plus FOLFOX4), Bristol-Myers Squibb/ImClone Systems/Merck KGaA's Erbitux (plus FOLFIRI), and Pfizer's Sutent (plus FOLFIRI)-consist of a targeted agent combined with an existing chemotherapy regimen. Experts interviewed believe that all three emerging therapies will demonstrate efficacy similar to that of currently available bevacizumab- containing regimens. However, the safety and tolerability attributes of CAPOX plus bevacizumab differentiate the regimen from all other current and emerging therapies and ensure its gold-standard status through 2016.

About the Report

Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival over IFL plus Bevacizumab to Reach Blockbuster Status is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

'Cost Estimator' Helps To Fill the Information Gap for North Carolina Health Plan Members

View Now